PMID- 28124959
OWN - NLM
STAT- MEDLINE
DCOM- 20170831
LR  - 20191113
IS  - 0374-9096 (Print)
IS  - 0374-9096 (Linking)
VI  - 50
IP  - 4
DP  - 2016 Oct
TI  - [Prevalence of human leukocyte antigen (HLA)-B*57:01 in HIV-infected patients].
PG  - 544-551
AB  - Deaths related with human immunodeficiency virus (HIV) infections have been 
      decreased by the introduction of combined anti-retroviral therapy (ART) into the 
      clinical practice. Combined ART usually consists of two nucleoside/nucleotide 
      analogs reverse transcriptase inhibitors (NRTI) that is called backbone and a 
      third drug that belongs to either non-nucleoside/nucleotide reverse transcriptase 
      inhibitors (NNRTI), protease inhibitors (PI), integrase strand transfer 
      inhibitors (INSTI) or entry inhibitors. During abacavir therapy which is a member 
      of NRTI, hypersensitivity reactions can occur approximately 4-9% of the patients 
      that lead difficulties for the management of HIV infections. It is known that, 
      the development of hypersensitivity reactions to abacavir is strongly associated 
      with the presence of HLA-B*57:01 allel, therefore, HLA-B*57:01 screening should 
      be performed prior to abacavir use. Since there is no data on HLA-B*57:01 
      prevalence in HIV-1-infected cases in Turkey, this is the first study that 
      screened HLA-B*57:01 allels among HIV-1 infected adults in Turkey. A total of 100 
      HIV-1-infected patients (81 male, 19 female; mean age: 42.31+/-11.97 years) who 
      have admitted to the Department of Infectious Diseases and Clinical Microbiology 
      of Ondokuz Mayis University School of Medicine, Samsun, Turkey, were included in 
      the study. Genomic DNAs were isolated from the blood samples of patients by using 
      a commercial spin column procedure (QIAamp(R) DNA Blood Mini Kit; QIAGEN GmbH, 
      Germany). HLA-B*57:01 genotyping was performed by the method of sequence-specific 
      primer (SSP)-based amplification using a commercial OlerupSSP(R) HLA-B*57:01 
      high-resolution test kit (Olerup SSP AB, Sweden) according to the manufacturer's 
      protocol. The products of polymerase chain reaction were electrophoresed on a 2% 
      agarose gel stained with Olerup SSP GelRed dye (Olerup SSP AB, Sweden), and the 
      bands were evaluated under UV light. In our study, three (2 male, 1 female) out 
      of 100 patients were found positive for HLA-B*57:01 gene with a prevalence of 3%, 
      which is a moderate level. Although the medical usefulness of HLA-B*57:01 
      screening before the abacavir therapy is emphasized, it was also noted that this 
      application is not cost-effective for the populations with low HLA-B*57:01 
      prevalence, in contrast to populations with high prevalence. Considering of the 
      incidence of HIV/AIDS in Turkey which is 0.12, the value and cost-effectiveness 
      of HLA-B*57:01 screening in HIV-1 positive cases before abacavir therapy should 
      be analysed by further studies.
FAU - Deveci, Aydin
AU  - Deveci A
FAU - Coban, Ahmet Yilmaz
AU  - Coban AY
AD  - Ondokuz Mayis University Faculty of Medicine, Department of Medical Microbiology, 
      Samsun, Turkey. cobanay2003@gmail.com.
FAU - Durupinar, Belma
AU  - Durupinar B
LA  - tur
PT  - Journal Article
TT  - HIV ile enfekte hastalarda insan lokosit antijeni (HLA)-B*57:01 prevalansi.
PL  - Turkey
TA  - Mikrobiyol Bul
JT  - Mikrobiyoloji bulteni
JID - 7503830
RN  - 0 (Anti-Retroviral Agents)
RN  - 0 (Dideoxynucleosides)
RN  - 0 (HLA-B Antigens)
RN  - 0 (Reverse Transcriptase Inhibitors)
RN  - WR2TIP26VS (abacavir)
SB  - IM
MH  - Adult
MH  - Alleles
MH  - Anti-Retroviral Agents/adverse effects/*therapeutic use
MH  - Dideoxynucleosides/adverse effects/therapeutic use
MH  - Female
MH  - HIV Infections/drug therapy/epidemiology/*immunology
MH  - HLA-B Antigens/*blood/genetics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Reverse Transcriptase Inhibitors/adverse effects/therapeutic use
MH  - Turkey/epidemiology
EDAT- 2017/01/27 06:00
MHDA- 2017/09/01 06:00
CRDT- 2017/01/27 06:00
PHST- 2017/01/27 06:00 [entrez]
PHST- 2017/01/27 06:00 [pubmed]
PHST- 2017/09/01 06:00 [medline]
AID - 10.5578/mb.29179 [doi]
PST - ppublish
SO  - Mikrobiyol Bul. 2016 Oct;50(4):544-551. doi: 10.5578/mb.29179.